

Press Release

Press Release

CONTACT: Andrew Bright
+ 1 (484) 530 3922
andrew.bright@oncure.com
www.oncure.com

PREMIER SELECTS ONCURE™ TO PROVIDE MEMBERSHIP WITH EXCLUSIVE PROSTATE BRACHYTHERAPY PRODUCTS UNDER TWO NEW THREE-YEAR AGREEMENTS

Plymouth Meeting, PA, June 9, 2004—ONCURE, the leading provider of minimally invasive prostate cancer treatment products, and Premier Purchasing Partners, the group purchasing division of one of the nation's leading strategic alliances of hospitals and health care systems, announced today that ONCURE has been awarded two three-year brachytherapy contracts to provide Premier members with the complete line of brachytherapy seeds products.

Premier's Radiation Oncology and Imaging Committees developed the recommendation for ONCURE's product line. Consisting of hospital staff with expertise in radiation oncology, medical physics, administration, and finance; the group determined that the products and the company's response to Premier's request for contract proposals best met members' clinical needs. The dual source agreements will begin on August 1, 2004, and will run for a three-year term. The agreements offer Premier's membership competitive market pricing and access to the most complete and clinically proven brachytherapy product line.

Under the terms of one agreement, ONCURE will provide Premier's membership with access to its Iodine-125 brachytherapy portfolio. OncoSeed™ is the leading prostate brachytherapy seed, and the only seed with fifteen years of peer-reviewed and published clinical data. RAPID Strand™ is an innovative brachytherapy product that is associated with improved radiation delivery; which in turn correlates with effective therapy. RAPID Strand shares the same long-term clinical data offered by OncoSeed. The second agreement covers seeds containing Palladium-103, another less frequently used type of seed.

ONCURA, a business of Amersham plc, is the global leader in minimally invasive prostate cancer treatment and was created through the merger of Amersham's brachytherapy business with Galil Medical Ltd.'s urology business. Headquartered in the United States, ONCURA operates as an independent business of Amersham plc, with Galil holding a minority position of 25 percent. ONCURA has a major presence in the treatment of prostate cancer. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.

Premier, Inc. is a strategic alliance in U.S. healthcare, entirely owned by 200 of the nation's leading not-for-profit hospital and healthcare systems. These systems operate or are affiliated with 1,500 hospital facilities and hundreds of other care sites. Premier provides an array of resources supporting health services delivery in the key areas of supply chain improvement and group purchasing, comparative data and benchmarking, safety, and insurance programs. Headquartered in San Diego, CA, Premier has offices in Chicago, IL; Charlotte, NC; and Washington, DC. For more information, visit www.premierinc.com.